Cancer Cell uses editorial assessment plus external peer review, and Cell Press can run consultative (cross-referee) review where reviewers see each other's comments. Practical implications:
| Reviewer ask | Response mode |
|---|---|
| "Does this hold in vivo / in patients?" | New experiment (highest priority) — plan via cc-study-design |
| "Cell line unauthenticated / antibody not validated" | Rigor fix — cc-reporting-standards |
| "n unclear / pseudo-replication / wrong test" | Reanalyze + report — cc-statistics |
| "Representative image without quantification" | Quantify across replicates — cc-figures-tables |
| "Overstated claim" | Narrow the claim — cc-writing-style |
| "Missing control / rescue" | Add control experiment |
| Disagreement / out-of-scope request | Respectful, evidence-based pushback |
For each comment:
Open the response with a brief summary of the major new experiments and how the paper improved. Keep tone professional and concrete; reviewers and editor read this closely.
n, randomization, blinding, deposition of any new datasets).cc-submission preflight before resubmitting.Reviewer 2, comment 3 (verbatim): "The MARK7 phenotype is shown only in cell lines. Does loss of MARK7 restrain tumor growth in an immunocompetent in vivo setting?"
Response (the Cancer Cell pattern):
We agree this was the central gap. We generated Mark7-conditional autochthonous tumors and, in a new Figure 5D–F, show that MARK7 loss reduced tumor burden and restored intratumoral CD8⁺ T cell infiltration (n=9 vs. 10 mice; randomized to arms; blinded histology scoring; log-rank p reported in the legend). The in vivo RNA-seq is deposited under GEO [accession] (KRT updated). We have accordingly revised the Summary and Discussion to state a "candidate vulnerability for checkpoint combination" rather than a "therapeutic target," matching the evidence now in hand.
Note the moves: it concedes the point, delivers the highest-value experiment (in vivo, immunocompetent),
carries full rigor (n, randomization, blinding), deposits the new data, and narrows the claim in the
same breath — the reviewer sees the manuscript improve, not merely defend itself.
Because reviewers may see each other's reports, a rebuttal that dismisses one referee can alienate the panel. When you decline an experiment:
n of 3, no
blinded scoring) — reviewers notice the rigor drop immediately.n; new datasets depositedn)【Decision】major / minor revision
【Essential points】editor-flagged: [...]
【Cross-cutting concern】...
【New experiments planned】(rigor + n + deposition): [...]
【Per-comment plan】R1.1 → ...; R1.2 → ...; R2.1 → ...
【Claims to narrow】...
【Pushback (with rationale)】...
【Next step】execute revisions → re-run cc-submission preflight